Larimar Therapeutics reports preliminary cash position of $136.9M as of Dec 31, 2025

Larimar Therapeutics, Inc.

Preliminary cash, cash equivalents and marketable securities of $136.9M as of Dec 31, 2025, unaudited.
Amount is subject to completion of quarter-end and year-end financial close procedures.
Full year 2025 financial results will be included in the upcoming Form 10-K filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.